{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:22:09Z","timestamp":1784784129801,"version":"3.55.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.clml.2025.02.009","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T18:37:54Z","timestamp":1740076674000},"page":"e474-e486.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Plasma Cytokine and Chemokine Profiles Predict Efficacy and Toxicity of Anti-CD19 CAR-T Cell Therapy in Large B-Cell Lymphoma"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6432-3114","authenticated-orcid":false,"given":"Fanyuan","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8955-7494","authenticated-orcid":false,"given":"Hanwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tenzin","family":"Passang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Funk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Wyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2468-967X","authenticated-orcid":false,"given":"Colin B.","family":"O'Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5723-1721","authenticated-orcid":false,"given":"Aseala I.","family":"Abousaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manali","family":"Rupji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita M.","family":"Dhodapkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0816-6729","authenticated-orcid":false,"given":"Edmund K.","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean L.","family":"Koff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.clml.2025.02.009_bib0001","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.clml.2025.02.009_bib0002","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.02.009_bib0003","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.02.009_bib0004","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.clml.2025.02.009_bib0005","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2025.02.009_bib0006","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/EDBK_238691","article-title":"The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden","volume":"39","author":"Santomasso","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet"},{"key":"10.1016\/j.clml.2025.02.009_bib0007","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"issue":"21","key":"10.1016\/j.clml.2025.02.009_bib0008","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.02.009_bib0009","first-page":"39","article-title":"Role of bridging therapy during chimeric antigen receptor T cell therapy","volume":"3","author":"Bhaskar","year":"2021","journal-title":"EJHaem"},{"issue":"1","key":"10.1016\/j.clml.2025.02.009_bib0010","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41375-022-01739-2","article-title":"Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma","volume":"37","author":"Alarcon Tomas","year":"2023","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2025.02.009_bib0011","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1080\/10428194.2020.1849676","article-title":"Relapsed\/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy","volume":"62","author":"Di Rocco","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.clml.2025.02.009_bib0012","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","article-title":"Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma","volume":"28","author":"Scholler","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.clml.2025.02.009_bib0013","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.02.009_bib0014","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1182\/blood-2018-99-116539","article-title":"Prediction of CAR T-related toxicities in R\/R DLBCL patients treated with Axicabtagene Ciloleucel using point of care cytokine measurements","volume":"132","author":"Faramand","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.02.009_bib0015","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"issue":"2, Supplement","key":"10.1016\/j.clml.2025.02.009_bib0016","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.jtct.2023.12.251","article-title":"Early prediction of severe icans after CD19 CAR T-cell therapy based on serum ferritin levels","volume":"30","author":"Huang","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.clml.2025.02.009_bib0017","doi-asserted-by":"crossref","first-page":"6418","DOI":"10.1038\/s41467-022-34242-4","article-title":"Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma","volume":"13","author":"Ravindranathan","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2025.02.009_bib0018","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-23-3628","article-title":"VPAC2 Receptor signaling promotes growth and immunosuppression in pancreatic cancer","author":"Passang","year":"2024","journal-title":"Cancer Res"},{"issue":"27","key":"10.1016\/j.clml.2025.02.009_bib0019","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and Non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.02.009_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.CCM.0000149854.61192.DC","article-title":"Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury*","volume":"33","author":"Parsons","year":"2005","journal-title":"Crit Care Med"},{"key":"10.1016\/j.clml.2025.02.009_bib0021","series-title":"Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. KDD \u201916","first-page":"785","article-title":"XGBoost: a scalable tree boosting system","author":"Chen","year":"2016"},{"key":"10.1016\/j.clml.2025.02.009_sbref0022","series-title":"A next-generation hyperparameter optimization framework","author":"Akiba","year":"2019"},{"key":"10.1016\/j.clml.2025.02.009_bib0023","unstructured":"Keany E. BorutaShap: a wrapper feature selection method which combines the Boruta feature selection algorithm with Shapley values. 2020. doi:10.5281\/zenodo.4247618."},{"issue":"11","key":"10.1016\/j.clml.2025.02.009_bib0024","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v036.i11","article-title":"Feature selection with the Boruta package","volume":"36","author":"Kursa","year":"2010","journal-title":"J Stat Softw"},{"key":"10.1016\/j.clml.2025.02.009_sbref0025","article-title":"A unified approach to interpreting model predictions","volume":"30","author":"Lundberg","year":"2017"},{"issue":"1","key":"10.1016\/j.clml.2025.02.009_bib0026","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s42256-019-0138-9","article-title":"From local explanations to global understanding with explainable AI for trees","volume":"2","author":"Lundberg","year":"2020","journal-title":"Nat Mach Intell"},{"issue":"214","key":"10.1016\/j.clml.2025.02.009_bib0027","first-page":"1","article-title":"Responsible machine learning with interactive explainability and fairness in Python","volume":"22","author":"Baniecki","year":"2021","journal-title":"J Mach Learn Res"},{"issue":"7172","key":"10.1016\/j.clml.2025.02.009_bib0028","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/bmj.317.7172.1572","article-title":"Survival probabilities (the Kaplan-Meier method)","volume":"317","author":"Bland","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.clml.2025.02.009_bib0029","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.publhealth.20.1.145","article-title":"Time-dependent covariates in the cox proportional-hazards regression model","volume":"20","author":"Fisher","year":"1999","journal-title":"Annu Rev Public Health"},{"key":"10.1016\/j.clml.2025.02.009_bib0030","series-title":"The Corsini Encyclopedia of Psychology","first-page":"1","article-title":"Mann-Whitney U test","author":"McKnight","year":"2010"},{"issue":"20","key":"10.1016\/j.clml.2025.02.009_bib0031","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1002\/sim.2174","article-title":"Adjusted Kaplan\u2013Meier estimator and log-rank test with inverse probability of treatment weighting for survival data","volume":"24","author":"Xie","year":"2005","journal-title":"Stat Med"},{"key":"10.1016\/j.clml.2025.02.009_bib0032","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133 17","author":"Hirayama","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.02.009_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.947648","article-title":"Cytokines as an important player in the context of CAR-T cell therapy for cancer: their role in tumor immunomodulation, manufacture, and clinical implications","volume":"13","author":"Silveira","year":"2022","journal-title":"Front Immunol"},{"issue":"22","key":"10.1016\/j.clml.2025.02.009_bib0034","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1182\/bloodadvances.2023010364","article-title":"Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R\/R DLBCL","volume":"7","author":"Blumenberg","year":"2023","journal-title":"Blood Adv"},{"issue":"22","key":"10.1016\/j.clml.2025.02.009_bib0035","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.clml.2025.02.009_bib0036","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1182\/bloodadvances.2022009309","article-title":"A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma","volume":"7","author":"Shouse","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.02.009_bib0037","first-page":"OF1","article-title":"Baseline serum inflammatory proteins predict poor CAR T outcomes in diffuse large B-cell lymphoma","author":"Faramand","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"2","key":"10.1016\/j.clml.2025.02.009_bib0038","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/bloodadvances.2023010607","article-title":"Nonactivated and IL-7 cultured CD19-specific CAR T cells are enriched in stem cell phenotypes and functionally superior","volume":"8","author":"Wang","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.clml.2025.02.009_bib0039","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.canlet.2014.12.047","article-title":"The role of IL-21 in immunity and cancer","volume":"358","author":"Davis","year":"2015","journal-title":"Cancer Lett"},{"issue":"4","key":"10.1016\/j.clml.2025.02.009_bib0040","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jcyt.2017.10.001","article-title":"A new approach to CAR T-cell gene engineering and cultivation using piggyBac transposon in the presence of IL-4, IL-7 and IL-21","volume":"20","author":"Pt\u00e1\u010dkov\u00e1","year":"2018","journal-title":"Cytotherapy"},{"issue":"3","key":"10.1016\/j.clml.2025.02.009_bib0041","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/2326-6066.CIR-19-0293","article-title":"Glypican-3\u2013Specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma","volume":"8","author":"Batra","year":"2020","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"10.1016\/j.clml.2025.02.009_bib0042","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ccell.2019.02.009","article-title":"Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets","volume":"35","author":"Cassetta","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2025.02.009_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.950213","article-title":"CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma via M2 macrophage interactions: a bioinformatic analysis of the tumor microenvironment","volume":"13","author":"Lou","year":"2022","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.clml.2025.02.009_bib0044","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.neuron.2022.12.009","article-title":"Microglia drive transient insult-induced brain injury by chemotactic recruitment of CD8+ T lymphocytes","volume":"111","author":"Shi","year":"2023","journal-title":"Neuron"},{"key":"10.1016\/j.clml.2025.02.009_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105829","article-title":"Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer","volume":"174","author":"Lu","year":"2021","journal-title":"Pharmacol Res"},{"issue":"6","key":"10.1016\/j.clml.2025.02.009_bib0046","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2025.02.009_bib0047","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1182\/blood-2023-174506","article-title":"A pro-inflammatory State and peak cytokines are associated with toxicity and early responses in real-world multiple myeloma patients treated with Idecabtagene Vicleucel","volume":"142","author":"Hansen","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.02.009_bib0048","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.arcmed.2020.05.009","article-title":"Tocilizumab: a therapeutic option for the treatment of Cytokine Storm syndrome in COVID-19","volume":"51","author":"Saha","year":"2020","journal-title":"Arch Med Res"},{"issue":"6","key":"10.1016\/j.clml.2025.02.009_bib0049","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clml.2025.02.009_bib0050","article-title":"CCL13 and human diseases","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.clml.2025.02.009_bib0051","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1172\/JCI87828","article-title":"Granulocyte macrophage colony-stimulating factor induces CCL17 production via IRF4 to mediate inflammation","volume":"126","author":"Achuthan","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clml.2025.02.009_bib0052","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.577027","article-title":"Cytokines in CAR T cell\u2013associated neurotoxicity","volume":"11","author":"Gust","year":"2020","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.clml.2025.02.009_bib0053","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/neuonc\/noac034","article-title":"Neurotoxicity following CD19\/CD28\u03b6 CAR T-cells in children and young adults with B-cell malignancies","volume":"24","author":"Shalabi","year":"2022","journal-title":"Neuro-Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.02.009_bib0054","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.02.009_bib0055","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12974-016-0503-0","article-title":"TGF-beta1 regulates human brain pericyte inflammatory processes involved in neurovasculature function","volume":"13","author":"Rustenhoven","year":"2016","journal-title":"J Neuroinflammation"},{"issue":"12","key":"10.1016\/j.clml.2025.02.009_bib0056","doi-asserted-by":"crossref","first-page":"22092","DOI":"10.3390\/ijms151222092","article-title":"TGF-\u03b21 protection against A\u03b21\u201342-induced neuroinflammation and neurodegeneration in rats","volume":"15","author":"Shen","year":"2014","journal-title":"Int J Mol Sci"},{"issue":"15_suppl","key":"10.1016\/j.clml.2025.02.009_bib0057","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1200\/JCO.2017.35.15_suppl.7024","article-title":"Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19-28z CAR T cells in adult patients with relapsed B-ALL","volume":"35","author":"Park","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.02.009_bib0058","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41421-023-00625-0","article-title":"Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma","volume":"10","author":"Lei","year":"2024","journal-title":"Cell Discov"},{"issue":"12","key":"10.1016\/j.clml.2025.02.009_bib0059","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1182\/blood.2021012561","article-title":"Donor plasmacytoid dendritic cells limit graft-versus-host disease through vasoactive intestinal polypeptide expression","volume":"140","author":"Zhu","year":"2022","journal-title":"Blood"},{"issue":"1\u20132","key":"10.1016\/j.clml.2025.02.009_bib0060","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0006-8993(99)02375-6","article-title":"Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease","volume":"854","author":"Offen","year":"2000","journal-title":"Brain Res"},{"issue":"1","key":"10.1016\/j.clml.2025.02.009_bib0061","doi-asserted-by":"crossref","first-page":"77.e1","DOI":"10.1016\/j.jtct.2023.10.017","article-title":"Real-world outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: a systematic review and meta-analysis","volume":"30","author":"Jacobson","year":"2024","journal-title":"Transplantat Cell Ther"},{"issue":"19","key":"10.1016\/j.clml.2025.02.009_bib0062","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2025.02.009_bib0063","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1158\/2643-3230.BCD-23-0112","article-title":"Product attributes of CAR T-cell therapy differentially associate with efficacy and toxicity in second-line large B-cell lymphoma (ZUMA-7)","volume":"5","author":"Filosto","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"10.1016\/j.clml.2025.02.009_bib0064","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:17:14Z","timestamp":1762600634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025000710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":64,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2152265025000710"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.02.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma Cytokine and Chemokine Profiles Predict Efficacy and Toxicity of Anti-CD19 CAR-T Cell Therapy in Large B-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}